Improved liver function and regeneration with A20

A20 改善肝功能和再生

基本信息

  • 批准号:
    6570013
  • 负责人:
  • 金额:
    $ 35.63万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-01-01 至 2007-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Necrosis and apoptosis of hepatocytes are critical pathologic features associated with liver injury. Hepatocyte apoptosis is a feature of viral hepatitis, ischemic liver injury, sepsis, cholestasis, and a result of exposure to hepatotoxic substances such as ethanol, acetaminophen and cytostatic drugs. Massive hepatocyte apoptosis and necrosis result in fulminant hepatic failure (FHF). Only 14% of patients diagnosed with FHF recover with medical therapy. Orthotopic liver transplantation (OLT) has dramatically improved the fate of these patients (49% undergo OLT), yet 37% die while awaiting OLT. This gloomy picture is balanced by the unique capacity of the liver to regenerate. Hepatocyte replication leads to a full recovery of liver function and mass 1-2 weeks following surgical, viral or chemical hepatic loss. We propose that protecting hepatocytes from apoptosis and promoting their proliferation are two strategies that could beneficially impact FHF. Our preliminary data demonstrate that A20 promotes hepatocyte proliferation and is anti-apoptotic. A20 is part of the physiologic response of hepatocytes to injury. A20 is upregulated in hepatocytes by pro-inflammatory stimuli including TNF and LPS and functions to protect from TNF mediated apoptosis. Gene transfer of A20 to mice livers protects from lethality in the galactosamine and LPS (D-gal/LPS) model of toxic FHF. Adenovirus mediated expression of A20 in livers of BALB/c mice yields an 89% survival rate following administration of D-gal/LPS as compared to 15-20% in control mice. Mice expressing A20 maintain normal liver function as assessed by prothrombin time while controls suffer from a severe bleeding diathesis. Expression of A20 in the liver protects from lethality associated with a subtotal (87%) liver resection (LR). In this model, resection of 87% of the liver mass results in 100% lethality. In contrast, >60% of mice expressing A20 survive the 87% LR and demonstrate increased regenerative capacity as assessed by the number of PCNA (proliferating cell nuclear antigen) positive nuclei in the liver. These results qualify A20 as a critical gene involved in accelerating liver regeneration and promoting hepatocyte survival and function, even when facing extreme metabolic demands. These encouraging results prompted the submission of this proposal. Our specific aims are i) to dissect, in vitro, the molecular basis of the (1) anti-apoptotic and (2) pro-proliferative function of A20 in hepatocytes and ii) to confirm that liver directed gene therapy using A20 will beneficially impact upon toxic, FAS-mediated and surgical experimental models of FHF. From a basic science standpoint, the in vitro work proposed will address the effect of A20 upon transcription factors and expression of genes involved in apoptosis, activation and proliferation of hepatocytes. This should unveil many unknowns in our understanding of hepatocyte biology and could lead to the discovery of novel therapeutic targets. From a therapeutic standpoint, validation of the beneficial effect of A20 in the murine in vivo models of FHF should set the basis for extending this approach to models of FHF in non human primates and potentially to clinical applications. The generation of novel safer and tissue specific viral vectors for gene transfer and the development of non-viral means of protein delivery to cells will facilitate clinical translation of A20 based therapies.
描述(申请人提供):肝细胞坏死和凋亡是与肝损伤相关的关键病理特征。肝细胞凋亡是病毒性肝炎、缺血性肝损伤、败血症、胆汁淤积以及暴露于肝毒性物质(如乙醇、对乙酰氨基酚和细胞抑制药物)的结果。大量肝细胞凋亡和坏死导致暴发性肝衰竭(FHF)。诊断为FHF的患者中只有14%通过药物治疗得以康复。原位肝移植(OLT)极大地改善了这些患者的命运(49%接受了OLT),但37%的患者在等待OLT期间死亡。肝脏独特的再生能力平衡了这种令人沮丧的局面。肝细胞复制导致手术、病毒性或化学性肝丧失后1-2周肝功能和肿块的完全恢复。我们提出保护肝细胞免于凋亡和促进其增殖是两种可能对FHF有益的策略。我们的初步数据表明,A20促进肝细胞增殖和抗凋亡。A20是肝细胞对损伤生理反应的一部分。A20在肝细胞中通过TNF和LPS等促炎刺激上调,并起保护TNF介导的细胞凋亡的作用。在半乳糖胺和LPS (D-gal/LPS)模型中,A20基因转移到小鼠肝脏可保护毒性FHF的致死性。腺病毒介导的A20在BALB/c小鼠肝脏中的表达在给予D-gal/LPS后获得89%的存活率,而对照组小鼠的存活率为15-20%。通过凝血酶原时间评估,表达A20的小鼠肝功能维持正常,而对照组则出现严重出血。肝脏中A20的表达保护了与次全肝切除(87%)相关的致死性。在这个模型中,切除87%的肝肿块导致100%的死亡率。相比之下,60%的表达A20的小鼠在87%的LR中存活下来,并且通过肝脏中增殖细胞核抗原(PCNA)阳性细胞核的数量来评估其再生能力。这些结果证明A20是加速肝脏再生和促进肝细胞存活和功能的关键基因,即使在面临极端代谢需求时也是如此。这些令人鼓舞的结果促使提出了这项建议。我们的具体目标是i)在体外解剖(1)肝细胞中A20抗凋亡和(2)促增殖功能的分子基础;ii)确认使用A20进行肝定向基因治疗将对FHF的毒性、fas介导和手术实验模型产生有益影响。从基础科学的角度来看,提出的体外工作将解决A20对肝细胞凋亡、活化和增殖相关转录因子和基因表达的影响。这将揭示我们对肝细胞生物学的理解中的许多未知因素,并可能导致新的治疗靶点的发现。从治疗的角度来看,验证A20在小鼠体内FHF模型中的有益作用应该为将该方法扩展到非人灵长类动物的FHF模型以及潜在的临床应用奠定基础。用于基因转移的新型更安全、组织特异性的病毒载体的产生,以及向细胞递送蛋白质的非病毒手段的发展,将促进基于A20的治疗方法的临床转化。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHRISTIANE FERRAN其他文献

CHRISTIANE FERRAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHRISTIANE FERRAN', 18)}}的其他基金

Harvard Longwood Short-Term Research Training in Vascular Surgery
哈佛朗伍德血管外科短期研究培训
  • 批准号:
    10250460
  • 财政年份:
    2013
  • 资助金额:
    $ 35.63万
  • 项目类别:
A20 Gene Polymorphisms in LDLT
LDLT 中的 A20 基因多态性
  • 批准号:
    8103756
  • 财政年份:
    2011
  • 资助金额:
    $ 35.63万
  • 项目类别:
A20 Gene Polymorphisms in LDLT
LDLT 中的 A20 基因多态性
  • 批准号:
    8308345
  • 财政年份:
    2011
  • 资助金额:
    $ 35.63万
  • 项目类别:
Vascular Remodeling in Transplant Arteriosclerosis
移植动脉硬化的血管重塑
  • 批准号:
    7030193
  • 财政年份:
    2006
  • 资助金额:
    $ 35.63万
  • 项目类别:
Vascular Remodeling in Transplant Arteriosclerosis
移植动脉硬化的血管重塑
  • 批准号:
    7244395
  • 财政年份:
    2006
  • 资助金额:
    $ 35.63万
  • 项目类别:
Vascular Remodeling in Transplant Arteriosclerosis
移植动脉硬化的血管重塑
  • 批准号:
    7433331
  • 财政年份:
    2006
  • 资助金额:
    $ 35.63万
  • 项目类别:
Vascular Remodeling in Transplant Arteriosclerosis
移植动脉硬化的血管重塑
  • 批准号:
    7629168
  • 财政年份:
    2006
  • 资助金额:
    $ 35.63万
  • 项目类别:
Improved liver function and regeneration with A20
A20 改善肝功能和再生
  • 批准号:
    6840549
  • 财政年份:
    2003
  • 资助金额:
    $ 35.63万
  • 项目类别:
Improved liver function and regeneration with A20
A20 改善肝功能和再生
  • 批准号:
    6693848
  • 财政年份:
    2003
  • 资助金额:
    $ 35.63万
  • 项目类别:
Improved liver function and regeneration with A20
A20 改善肝功能和再生
  • 批准号:
    7761195
  • 财政年份:
    2003
  • 资助金额:
    $ 35.63万
  • 项目类别:

相似国自然基金

Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 批准年份:
    2020
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 批准年份:
    2017
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 批准年份:
    2016
  • 资助金额:
    58.0 万元
  • 项目类别:
    面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 批准年份:
    2014
  • 资助金额:
    73.0 万元
  • 项目类别:
    面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
  • 批准号:
    81301123
  • 批准年份:
    2013
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
  • 批准号:
    81101529
  • 批准年份:
    2011
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
  • 批准号:
    39500043
  • 批准年份:
    1995
  • 资助金额:
    9.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Early detection of radiation induced apoptosis by 99mTc-Annexin V andFDG in a lung cancer cell line.
99mTc-Annexin V 和 FDG 在肺癌细胞系中早期检测辐射诱导的细胞凋亡。
  • 批准号:
    22591357
  • 财政年份:
    2010
  • 资助金额:
    $ 35.63万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A study of cell survival mechanisms for apoptosis-resistant oral squamous cell carcinoma cell line
抗凋亡口腔鳞状细胞癌细胞系的细胞存活机制研究
  • 批准号:
    15592137
  • 财政年份:
    2003
  • 资助金额:
    $ 35.63万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Involvement molecular chaperone in apoptosis signaling in human salivary gland cell line
分子伴侣参与人唾液腺细胞系凋亡信号传导
  • 批准号:
    14571772
  • 财政年份:
    2002
  • 资助金额:
    $ 35.63万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Lactoferrin-induced apoptosis and PLD activation in oral squamous cell carcinoma cell line
乳铁蛋白诱导口腔鳞状细胞癌细胞系凋亡和 PLD 激活
  • 批准号:
    13672128
  • 财政年份:
    2001
  • 资助金额:
    $ 35.63万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
INVESTIGATION OF MECHANISMS OF CDDP-INDUCED APOPTOSIS IN THE CDDP-RESISTANT A431 CELL LINE
CDDP抗性A431细胞系中CDDP诱导凋亡机制的研究
  • 批准号:
    10671880
  • 财政年份:
    1998
  • 资助金额:
    $ 35.63万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Induction of Apoptosis to Rat Thyroid Follicular Epithelial Cell Line, FRTL-5 Cell
诱导大鼠甲状腺滤泡上皮细胞系 FRTL-5 细胞凋亡
  • 批准号:
    08670199
  • 财政年份:
    1996
  • 资助金额:
    $ 35.63万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Elucidation of the intracellular mechanisms of cisplatin-induced apoptosis in renal cell line
阐明顺铂诱导肾细胞系凋亡的细胞内机制
  • 批准号:
    08671297
  • 财政年份:
    1996
  • 资助金额:
    $ 35.63万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
C-MYC EXPRESSION AND APOPTOSIS IN A B CELL LINE
B 细胞系中的 C-MYC 表达和凋亡
  • 批准号:
    2089092
  • 财政年份:
    1984
  • 资助金额:
    $ 35.63万
  • 项目类别:
C-MYC EXPRESSION AND APOPTOSIS IN A B CELL LINE
B 细胞系中的 C-MYC 表达和凋亡
  • 批准号:
    2089091
  • 财政年份:
    1984
  • 资助金额:
    $ 35.63万
  • 项目类别:
C-MYC EXPRESSION AND APOPTOSIS IN A B CELL LINE
B 细胞系中的 C-MYC 表达和凋亡
  • 批准号:
    6164108
  • 财政年份:
    1984
  • 资助金额:
    $ 35.63万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了